期刊文献+

慢性乙型肝炎的干扰素治疗 被引量:10

Interferon therapy for chronic hepatitis B
原文传递
导出
摘要 慢性乙型肝炎已成为全球一个严重的健康问题。HBV慢性感染者可发展为肝硬化、失代偿肝病以及肝细胞肝癌。抗病毒治疗是陧性乙型肝炎最关键的治疗方法,持续抑制或清除HBV可改善肝脏炎症及纤维化,降低HBV相关并发症。目前公认有效的抗HBV药物主要包括干扰素和核苷酸类似物。
作者 汤伟亮 谢青
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2009年第10期726-729,共4页 Chinese Journal of Hepatology
关键词 肝炎 乙型 慢性 干扰素 预测因素 血清学转换 安全性 Hepatitis B, chronic Interferon Predication factor Serology exchange Safety
  • 相关文献

参考文献14

  • 1Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 2009, 49(5 Suppl):S 103-111.
  • 2Cootksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepattitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10: 298-305.
  • 3Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic heaptitis B. N Engl J Meal, 2005, 352: 2682-2695.
  • 4Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351: 1206-1217.
  • 5Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg- positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365: 123-129.
  • 6European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 2009, 50: 227-242.
  • 7Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut, 2007, 56: 699-705.
  • 8Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg positive chronic hepatitis B. Hepatology, 2008, 47: 428-434.
  • 9Buster EH, Flind HJ, Simsek H, et al. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up strdy in chronic hepatitis B patients. Am J Gastroenterol, 2009[Epub ahead of print].
  • 10Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49: 1151-1157.

同被引文献71

引证文献10

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部